Loading company…
Seoul-based biotech developing tuberculosis and other vaccines, cell-penetrating peptide technology and antimicrobial agents.
Founded in 2016 and based in Seoul, South Korea, Quratis Inc. is a biotechnology company that develops vaccines, cell therapy platforms and PNA-based antimicrobial agents. Its phase 2b/3 IND for a tuberculosis vaccine for adolescents and adults was approved in July 2022. The company also offers CMO and CDMO services. In October 2025 Wired Partners acquired 7.92 million shares at KRW 631 each, for KRW 5 billion, in a PIPE deal, bringing its stake to 11.87%. The company is at the Late stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in